{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132783","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.530937+00:00","generated_at":"2026-05-20T03:05:35.181909+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IN8bio Phase 1 INB-200 shows mPFS 16.1 months, more than double SOC in GBM","bullets":["Median PFS in repeated-dose patients reached 16.1 months vs 6.9 months historical SOC Stupp protocol.","Four patients (40%) receiving repeated doses remain alive and progression-free for median over two years.","No dose-limiting toxicities, CRS, or ICANS observed; most adverse events Grade 1-2.","Phase 2 INB-400 trial shows preliminary mPFS of 10.8 months; additional data expected late 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132783","json":"https://secwatch.observer/filing/0001193125-25-132783.json","markdown":"https://secwatch.observer/filing/0001193125-25-132783.md","text":"https://secwatch.observer/filing/0001193125-25-132783.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525132783/0001193125-25-132783-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525132783/d945167d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:05:35.181909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}